AnneMTraynorMD
Hematology • Madison, WIAssociate Professor, Medicine, University of Wisconsin Medical School
Dr. Traynor is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
600 Highland Ave
Madison, WI 53792Phone+1 608-265-1700Fax+1 608-265-8133- Is this information wrong?
Education & Training
University of Iowa Hospitals and ClinicsFellowship, Hematology and Medical Oncology, 1995 - 1997
Bassett Medical CenterResidency, Internal Medicine, 1990 - 1994
University of North Carolina at Chapel Hill School of MedicineClass of 1990
Certifications & Licensure
WI State Medical License 1997 - 2023
IL State Medical License 2005 - 2014
IA State Medical License 1994 - 1998
GA State Medical License 1994 - 1995
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2005 Jun 01
- Hypofractionated Radiotherapy for Lung Cancer Start of enrollment: 2004 Jun 01
- R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer Start of enrollment: 2007 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- Combining Dual Checkpoint Immunotherapy with Ablative Radiation to All Sites of Oligometastatic Non-Small Cell Lung Cancer: Toxicity and Efficacy Results of a Phase 1b...Michael F Bassetti, Brett A Morris, Nan Sethakorn, Joshua M Lang, Jennifer L Schehr, Shuang George Zhao, Zachary S Morris, Darya Buehler, Jens C Eickhoff, Paul M Harar...> ;International Journal of Radiation Oncology, Biology, Physics. 2024 Apr 1
- 6 citationsMRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.Kai He, David Berz, Shirish M Gadgeel, Wade T Iams, Debora S Bruno, Collin M Blakely, Alexander I Spira, Manish R Patel, David M Waterhouse, Donald A Richards, Anthony...> ;Journal of Thoracic Oncology. 2023 Jul 1
- 8 citationsA phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Canc...Tareq Salous, Nikhil A Shukla, Sandra K Althouse, Susan M Perkins, Muhammad Furqan, Ticiana Leal, Anne M Traynor, Lawrence E Feldman, Nasser H Hanna, Greg A Durm> ;Cancer. 2023 Jan 15
- Join now to see all
Press Mentions
Faculty Promotions at Purdue Approved by BoardApril 2nd, 2020
Biostatistics and Medical Informatics Tapped for $11.8 Million National Coordinating CenterOctober 2nd, 2019
Grant Support
- Pilot Study Of Liquid Crystal Nano-Structured Surfaces (Lc/Ns) AnalysesNational Center For Research Resources2007
- Phase II Study Of Suberoylanilide Hydroxamic Acid (SAHA) In Relapsed NsclcNational Center For Research Resources2007
- Phase II Trial Of Ps341/Dox In Metastatic Breast CancerNational Cancer Institute2006
- Stem Cell Transplant As Standard Treatment For Symptomatic Multiple MyelomaNational Center For Research Resources2000–2001
- Phase II Study Of Interleukin 12 For Plateau Phase Multiple MyelomaNational Center For Research Resources1999–2001
- Infusional 8 Chloro Cyclic AMP In Treatment Of Multiple MyelomaNational Center For Research Resources1999–2000
- Stem Cell Transplant As Standard Treatment For Multiple MyelomaNational Center For Research Resources1999
Professional Memberships
- Member
Hospital Affiliations
University HospitalMadison, Wisconsin
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
